Indivior Pharmaceuticals Inc.

Indivior Pharmaceuticals Inc. is a specialty pharmaceutical company dedicated to developing and commercializing treatments for opioid use disorder (OUD) and related conditions. The company's mission is to deliver evidence-based treatment and advance the understanding of OUD as a chronic, yet treatable, brain disease, aiming to help individuals achieve long-term recovery through accessible, science-driven care. Headquartered in North Chesterfield, Virginia, Indivior focuses on combating the opioid crisis by expanding access to effective treatments and working to eliminate the stigma associated with addiction.

Indivior's product portfolio primarily includes buprenorphine-based prescription drugs. Key products are Sublocade, a buprenorphine extended-release monthly injection, and Suboxone, a buprenorphine and naloxone sublingual film, both used for the treatment of opioid dependence. The company also offers Opvee (nalmefene hydrochloride nasal spray) for opioid overdose reversal and Perseris (risperidone). Indivior positions itself as a market leader in long-acting injectable medications for OUD and engages with healthcare providers, government agencies, and patient advocacy groups to promote awareness and education regarding addiction as a chronic disease.

In January 2026, Indivior completed its redomiciliation from the United Kingdom to the United States, with Indivior Pharmaceuticals Inc., a Delaware corporation, becoming the new parent company. Joe Ciaffoni was appointed Chief Executive Officer in May 2025. The company reported strong financial performance in Q1 2026, with total net revenue increasing by 19% year-over-year and Sublocade net revenue growing by 32%. However, Indivior also announced the cessation of internal development for two OUD drug candidates (INDV-2000 and INDV-6001) following a phase 2 trial that did not meet its primary endpoint, a decision expected to significantly impact its R&D organization.